Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 1/20 | 0.34 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17004586 | 1.00 | USP28 (0.34) | USP28USP25DGAT1PTGDR2PTPN7 | |
| SCHEMBL1173372 | 0.88 | DGAT1 (0.37) | USP28USP25DGAT1PTGDR2PTPN7 | |
| SCHEMBL1173257 | 0.88 | DGAT1 (0.37) | USP28USP25DGAT1PTGDR2PTPN7 | |
| SCHEMBL247850 | 0.88 | DGAT1 (0.37) | USP28USP25DGAT1PTGDR2PTPN7 | |
| Hydrochloric Acid SCHEMBL16462425 | 0.87 | DGAT1 (0.36) | USP28USP25DGAT1PTGDR2PTPN7 | |
| SCHEMBL3171484 | 0.81 | PTGDR2 (0.33) | DGAT1PTGDR2PTPN7DUSP3KDM1A | |
| SCHEMBL17004543 | 0.81 | ALDH1A1 (0.35) | PTGDR2CYP1A2 | |
| SCHEMBL17004542 | 0.81 | ALDH1A1 (0.35) | PTGDR2CYP1A2 | |
| SCHEMBL2585458 | 0.81 | DGAT1 (0.38) | USP28USP25DGAT1PTGDR2PTPN7 | |
| SCHEMBL2585455 | 0.81 | DGAT1 (0.38) | USP28USP25DGAT1PTGDR2PTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353163-B1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-05 | — | — | EP | disclosed |
| US-20180334447-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-22 | — | — | US | disclosed |
| EP-3353163-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017050978-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | WO | disclosed |
| EP-2297120-B1 | AMINODIHYDROTHIAZINE DERIVATIVES AS BACE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2015-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334447-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | BACE1, BACE2, APP | USP28 1822/4885USP25 1691/4885DGAT1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.